Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
Daiichi Sankyo said on June 26 that a key European regulatory panel has given the blessing for a label expansion of its TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan) for the treatment of triple-negative breast cancer (TNBC). The European Medicines…
To read the full story
Related Article
- Datroway Lands EU Approval in 1st-Line TNBC
August 3, 2026
- Datroway Snares US Approval in 1st-Line TNBC: Daiichi Sankyo
May 25, 2026
- Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
- Datroway Accepted for US Review for 1st-Line TNBC: Daiichi Sankyo
February 4, 2026
- Datroway Accepted for European Review for 1st Line TNBC
December 19, 2025
- Datroway Hits Key Goals in Global PIII Trial for TNBC: Daiichi Sankyo
October 7, 2025
- Daiichi Sankyo’s Datroway Approved in Europe for Breast Cancer
April 9, 2025
BUSINESS
- Terumo to Take US$610 Million Hit as CSL Plasma Supply Deal Ends
October 9, 2026
- TOPIX Shuffle Puts Mid-Tier Drug Makers, Wholesalers on Chopping Block
October 9, 2026
- Ono Gets Japan, Asia Rights to 3 IgG Degraders from Biohaven
October 9, 2026
- Datroway Snares TNBC Approval in China: Daiichi Sankyo
October 9, 2026
- Enhertu Gains Adjuvant Nod in China for HER2-Positive Breast Cancer
October 9, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…